Method for inducing cytotoxicity in cancer cells

Patent metadata

Field	Value
Publication number	US-10160773-B2
Application number	US-201815972723-A
Country	US
Kind code	B2
Filing date	May 7, 2018
Priority date	Oct 24, 2016
Publication date	Dec 25, 2018
Grant date	Dec 25, 2018

Abstract

A method for treating a proliferative disease, disorder, or condition comprising administering a gold(III) complex such as [Au(npen)Cl 2 ]Cl.2H 2 O (1) or [Au(npen) 2 ]Cl 3 (2); the complexes, and methods for making them.

First claim

The invention claimed is:

1. A method for inducing cytotoxicity against cancer cells in a subject in need thereof, comprising
administering a composition comprising a complex comprising Core (1) or a complex comprising Core (2), or both, one or more pharmaceutically acceptable excipients and a chemotherapeutic agent, into a site infiltrated by the cancer cells, while concurrently administering a radiation treatment to the subject;
wherein Core (1) and Core (2) have the following chemical structures:

wherein positions 1-14 of Core (1) or positions 1-28 of Core (2) are, independently, hydrogen, hydroxy, halogen, C1-C6 alkyl, or aryl, and
wherein said anion is a halogen and said anions are three halogens;
wherein growth of said cancer cells is inhibited by said complex of Core (1) or Core (2),
wherein said cancer cells are selected from the group consisting of breast cancer cells, lung cancer cells and colon cancer cells.

2. The method of claim 1 that comprises administering [Au(npen)Cl 2 ]Cl.2H 2 O (“complex 1”), wherein (npen) is meso-1,2-di(1-naphthyl)-1,2-diaminoethane.

3. The method of claim 1 that comprises administering [Au(npen) 2 ]Cl 3 (“complex 2”), wherein (npen) is meso-1,2-di(1-naphthyl)-1,2-diaminoethane.

Assignees

• Univ King Fahd Pet & Minerals

Inventors

• Isab Anvarhusein A
• Altaf Muhammad

Classifications

• A61K45/06

  Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca · CPC title

• A61K47/50

  the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates · CPC title

• C07F1/005 Primary

  without C-Metal linkages · CPC title

• A61K31/28

  Compounds containing heavy metals · CPC title

• A61K9/0053

  Mouth and digestive tract, i.e. intraoral and peroral administration · CPC title